Archive for May, 2021

$IDEX Argentine EV “Tito” Costs a Tiny Fraction of a Tesla $TSLA

Hell-bent on reducing their reliance on fossil fuels, countries around the world are determined to replace their vehicle fleets with zero-emission electric vehicles (“EVs”). Most of these countries are looking to gradually phase out the sale of internal combustion engine (“ICE”) vehicles over the next decade or two, but one factor stands in the way of widespread EV adoption. Most electric vehicles on the market are far too expensive for ordinary consumers, and some governments have taken to offering subsidies and tax rebates to make electric vehicles more affordable.

However, one EV model that definitely won’t need the government’s help to sell is the Coradir Tito. Produced by Argentinian company Coradir, the name Tito is a callback to the company’s founder Alberto Tito Corapi. The compact vehicle packs a whole lot in quite a small frame for only $15,000, or 300,000 Mexican pesos.

Individuals who purchase the vehicle during the pre-sale launch will be granted a 20% discount, reducing the cost of the EV down to $12,000 (250,000 pesos). With Tesla’s (NASDAQ: TSLA) cheapest EV model, the basic version of the Model 3, going for around $48,000, or 969,900 pesos, this means the Coradir Tito is worth just a quarter of Tesla’s cheapest electric vehicle.

While buy the Argentinian EV in pre-sale may cost substantially less, it’s important to note that the Tito, unfortunately, lacks important safety features such as airbags, stability control (“ESP”) and an anti-lock braking system (“ABS”).

Despite missing these security features, the Tito is still packed with plenty of features. Seating four people max, it is equipped with a 10-inch LED screen, power window lift, a folding rear seat, remote lock and backup camera, among other valuable features. The Tito is powered by a lithium-ion battery pack with a range of 100 kilometers (62 miles) and a top speed of 65 kilometers (47 miles) per hour. Additionally, it will take Tito’s battery, which has 2,000 charge and discharge cycles, around eight hours to fully charge on a 220v 50hz household outlet.

At the moment, only 50 units of the Argentinian electric vehicle are available for reservation, and they will be delivered within an estimated four months. However, note that the Tito currently cannot be driven on public roads in Argentina. According to the company behind the Coradir Tito, it is still undergoing the government approval process; it expects to receive a Model Configuration License by the end of the month.

As more innovations, such as charging EVs as a service offered by Ideanomics Inc. (NASDAQ: IDEX), enter the electric vehicle space, the popularity of these new vehicles is set to grow.

NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $IDEX Argentine EV “Tito” Costs a Tiny Fraction of a Tesla $TSLA

$CBDHF Issues Commendation on Proposed Hemp Access and Consumer Safety Act

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness company offering premium probiotic supplements and products containing CBD, commends the Hemp Access and Consumer Safety Act filed by Oregon Democratic Senators Ron Wyden and Jeff Merkley and Kentucky Republican Senator Rand Paul. The act aims to add hemp, hemp-derived cannabidiol or a substance containing any other ingredient derived from hemp to the definition of dietary supplement according to the Federal Food, Drug and Cosmetic Act and would remove certain restrictions that have blocked the emergence of legal consumable hemp products in the United States. “HempFusion is prepared for both GRAS (Generally Recognized as Safe) and NDIN (New Dietary Ingredient Notification), which separates us from the vast majority of CBD brands on the market today,” said Dr. Jason Mitchell, HempFusion’s co-founder and CEO. “We proudly endorse and commend The Hemp Access and Consumer Safety Act and thank Senators Wyden, Paul and Merkley for their bipartisan support. A major component of our strategic business plan has been to prepare for this day, and now we are finally at the door of what will open up the CBD industry for those brands that can properly adhere to FDA’s requirements.”

To view the full press release, visit https://ibn.fm/NO5du

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA drug listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.HempFusion.com or www.Probulin.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at http://ibn.fm/HempFusion

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $CBDHF Issues Commendation on Proposed Hemp Access and Consumer Safety Act

Gage Growth Corp. (CSE: GAGE) to be Included in Leading Cannabis ETF

Gage Growth (CSE: GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced that it will be included in AdvisorShares Pure US Cannabis ETF (NYSE: MSOS), a cannabis-focused, exchange-traded fund (“EFT”). A leading sponsor of actively managed ETFs, AdvisorShares Pure US Cannabis ETF is the first and only actively managed ETF listed in the United States that provides dedicated cannabis exposure; the EFT focuses exclusively on U.S. companies with an estimated $1 billion in assets under management. MSOS is dedicated to achieving long-term capital growth and works to reach that objective by investing in some of the largest foreign and domestic cannabis companies. “Inclusion in a leading ETF brings strong exposure to potential new investors, and we are pleased the AdvisorShares ETF has initiated a position in our company,” said Gage CEO Fabian Monaco in the press release. “This represents a strong milestone for the Company and provides us added exposure to the investment community, coupled with the success of our business in the cannabis marketplace. This milestone comes at a perfect time as we approach an exciting inflection point, which we believe will enable us to extend our strong growth as we look ahead in 2021.”

To view the full press release, visit https://ibn.fm/SAicH

About Gage Growth Corp.

Gage is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the company’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers, or dispensaries. For more information about the company, visit www.GageCannabis.com.

NOTE TO INVESTORS: The latest news and updates relating to GAGE are available in the company’s newsroom at http://ibn.fm/GAGE

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on Gage Growth Corp. (CSE: GAGE) to be Included in Leading Cannabis ETF

$UUUU Liquid Electricity Stocks: What to Know If You Want to Invest in the Futuristic “Wonder Fuel”

InvestorPlace – Stock Market News, Stock Advice & Trading Tips

Liquid electricity stocks seeing extra interest from investors that are looking for the green energy source of the future.

First, let’s talk about what liquid electricity is. The fuel source has a somewhat complex explanation. See, electricity is sent through electrolysers to create some fuels. That includes hydrogen, methanol, or ammonia. Hydrogen, in particular, is of interest here. It can be further processed into what we called liquid electricity.

Alex Koyfman argued in March that liquid electricity has the potential to be the fuel of the U.S. in the future. He said the following in a letter posted by WealthDaily.

“Despite what the mainstream media have been telling you for decades now, the future of consumer and commercial transportation is not electric. It also won’t be gas-powered…Instead, it will be a combination of the two, and it will all be made possible by a marvel of modern science — a wonder fuel — that few people even know exists. This fuel has a couple very unusual properties that make it so versatile and so clean that the entire global economy is likely to become dependent on it by the middle of the 21st century.”

So what are liquid electricity stocks that investors might want to start researching. That’s where things get tricky. While the process of creating liquid electricity has been around for some time, there are currently many companies investing in it. That means it’s hard to track down public companies you can buy stocks of in the U.S.

However, there are some public and private companies worth keeping an eye on. That includes ME EnergyFreudenberg, First VanadiumVictory MetalsEnergy Fuels (NYSEAMERICAN:UUUU), and others.

If you’re interested in green stocks, then we’ve got more info for you below.

InvestorPlace.com offers a wide variety of coverage for stocks and that includes green ones. A few examples of some with recent news include Ceres Power (OTCMKTS:CPWHF), Ideanomics (NASDAQ:IDEX), Canadian Solar (NASDAQ:CSIQ), and more. Learn about all of these below.

More Green Energy Stocks

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

Friday, May 21st, 2021 Uncategorized Comments Off on $UUUU Liquid Electricity Stocks: What to Know If You Want to Invest in the Futuristic “Wonder Fuel”

$CLXPF Strengthens IP Portfolio with 12th Patent Filing

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by the company. In the announcement, the company noted that the application discloses novel compositions anticipated to have improved pharmacokinetic profiles while retaining significant efficacy measures of the original molecules; the patent also discusses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybin’s psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof. In addition, the patent application outlines novel methods directed at leveraging the disclosed compositions to promote decreased time to therapeutic onset and duration of action, as well as fewer side effects. This new patent is synergistic with others filed by Cybin that are related to a delivery technology covering various chemically synthesized psychedelic molecules. “By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” stated Doug Drysdale, Chief Executive Officer.

To view the full press release, visit https://ibn.fm/ezPAU

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $CLXPF Strengthens IP Portfolio with 12th Patent Filing

$BRSF Committed to Expand Access to Neurological Care for Infected Patients Amid the Pandemic

  • Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring
  • Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk
  • BRSF’s sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient’s condition while minimizing cross-contamination risk

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals’ red zones amid the pandemic. As the Company describes in one of the recent articles published on the website, the consequences of the COVID-19 pandemic on brain health are significant (https://ibn.fm/fhYxm).

While respiratory damage of novel Coronavirus is well reported, debilitating and even deadly neurological conditions may be affecting far more people infected with the virus. As the pandemic unravels and we learn more about the COVID-19, it is becoming clear that, although COVID-19 does not appear to directly attack nerve tissue, it is neurologically damaging. It is known to cause neurological injury in 1 out of 7 patients hospitalized with the infection (https://ibn.fm/aTUhK). The list of neurological diseases associated with COVID-19 infection is long and includes encephalopathy, Guillain-Barré syndrome, hemorrhagic stroke, ischemic stroke, meningoencephalitis, paralysis, and seizures. A growing body of evidence suggests that COVID-19 can have serious and potentially long-lasting effects on the brain — as many as 1 in 3 COVID-19 survivors experience neurological or a mental health disorder within six months of the infection (https://ibn.fm/Bop48).

COVID-19 appears to cause neurological injury through three mechanisms, including hypoxemia — the state of very low blood oxygen levels causing encephalopathy and neurological damage; immune dysfunction causing “cytokine storm” and blood clots.

Neurological conditions associated with COVID-19 are challenging to diagnose. For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients. Investigative procedures such as MRI, lumbar puncture and cerebrospinal fluid analysis are complicated to perform on ICU patients that are on supportive care measures such as mechanical ventilation and supplemental oxygenation.

The quest for a diagnostic procedure that may offer a response in this extremely difficult and limiting setting is still ongoing – but EEG may be able to offer a solution.

EEG could be a potentially helpful study to conduct on patients with suspected COVID-19 encephalopathy. Bedside EEG testing may reveal occult, subclinical seizure activity that would otherwise go unveiled. Still, traditional EEG testing is a time-consuming task that requires placing electrodes and measuring the patient’s head, which all prolongs exposure of frontline health workers to the deadly virus.

When fighting a highly contagious disease, disposable technology is vital. This is where NeuroCap(TM) and NeuroEEG(TM), the Company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring. With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through equipment. BRSF’s EEG caps designed for single use are also easy to place – within minutes – which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $BRSF Committed to Expand Access to Neurological Care for Infected Patients Amid the Pandemic

$ATER Announces Execs Participation in Tech & Media Conference; Upcoming Conferences Outlined

Aterian (NASDAQ: ATER), a leading technology-enabled consumer products platform that builds, acquires, and partners with best-in-class e-commerce brands, announced that key management personnel participated in the 16th annual Needham Technology & Media Conference. Participants included co-founder & CEO Yaniv Sarig and CFO Arturo Rodriguez. The two ATER leaders were interviewed by Needham senior analyst Anna Andreeva during a key segment of the May 17, 2021, event. During the fireside chat, the pair discussed a variety of topics, including ATER’s corporate strategy. The discussion also covered how the company’s exclusive technology-enabled software platform AIMEE operates and how it impacts the success of not only ATER’s organic growth but also its acquisition strategy. The announcement also included the company’s plans to participate in the Jefferies Consumer & eCommerce Summit on May 25, the RBC Capital Markets Global Consumer & Retail Conference on June 2, and the Jefferies Virtual Consumer Conference & Digital Gaming Day on June 22.

To view the full press release, visit https://ibn.fm/YL0QA

About Aterian Inc.

Aterian is a leading technology-enabled consumer products platform that builds, acquires and partners with best-in-class e-commerce brands by harnessing proprietary software and an agile supply chain to create top-selling consumer products. The company’s cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine, or AIMEE(TM) (“AIMEE”), leverages machine learning, natural language processing and data analytics to streamline the management of products at scale across the world’s largest online marketplaces, including Amazon, Shopify and Walmart. Aterian has thousands of SKUs across 14 owned and operated brands and sells products in multiple categories, including home and kitchen appliances, health and wellness, beauty and consumer electronics. For more information about the company, visit www.Aterian.io.

NOTE TO INVESTORS: The latest news and updates relating to ATER are available in the company’s newsroom at http://ibn.fm/ATER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $ATER Announces Execs Participation in Tech & Media Conference; Upcoming Conferences Outlined

$AMPG New Trial Order among Positives That Could Drive Financial Turnaround

May 20, 2021

AmpliTech Group Inc.’s (NASDAQ: AMPG) New Trial Order among Positives That Could Drive Financial Turnaround

  • AmpliTech Group Inc. announced it had been selected to provide its ultra-low noise amplifiers
  • The trial order, issued by a major Fortune 200 defense contractor, is valued at approximately $120,000
  • The order for a space program offers AmpliTech the opportunity to demonstrate its capabilities
  • It is among other positives that, combined, could drive an important financial turnaround

AmpliTech Group (NASDAQ: AMPG, AMPGW) recently reached a milestone deemed an opportunity for the company to demonstrate its capabilities. The company, which designs, develops and manufactures custom radio frequency (“RF”) components for satellite communications (“SATCOM”), commercial, space, defense and military markets, as well as products for the 5G/6G wireless ecosystem, announced it had been selected by a major Fortune 200 defense contractor to provide its ultra-low noise amplifiers in a trial order valued at about $120,000 (https://ibn.fm/c9uCA).

AmpliTech, which prides itself on being a company built on experience, proven technical expertise, superior design heritage and complete customer satisfaction, has developed high-quality amplifiers for use in space-borne satellites and probes that orbit around the earth.

Given the rigors of launching and the requirement to maintain the highest performance in a space orbit for many years, AmpliTech builds these parts using specially developed techniques and procedures that it has continually perfected. The company focuses on being a reliable supplier of high-quality amplifiers for use in situations where the best performance is needed.

It is this quality that Fawad Maqbool, AmpliTech’s Founder and CEO, alluded to in his statement following the announcement. “Once again, the importance of having the leading-edge performance in the amplifiers is a major factor for the selection, along with our capability to deliver the highest quality as well,” he said.

This trial order for a space program buttresses Fawad’s outlook for the remainder of the fiscal year 2021. It follows a similarly positive announcement in which AmpliTech reported that its order backlog had reached $2.2 million at the end of the first quarter of 2021. At the time, Fawad noted that the increased backlog was indicative of growing demand and revenues in the upcoming quarters (https://ibn.fm/gN6Fy).

Combined, these positives will be instrumental in helping AMPG bounce back from a financially disappointing year that saw it report a net loss of $1.03 million for the period ended December 31, 2020, down from a net income of $5,945 in 2019. This sharp drop occurred despite an increase in revenue year over year of 11%.

According to its Form 10-K filing (https://ibn.fm/SJEYN), AmpliTech’s slip into the red was attributable to the Covid-19 pandemic, as well as an increase in costs related to selling and general and administrative expenses of approximately 46.24% from $1.48 million in 2019 to $2.17 million in 2020. Nonetheless, the company clarified that it expects to continue its business efforts and not shut down – due to pandemic-induced causes – unless otherwise mandated, but also painted a grim picture of 2021 in its outlook for the same reason.

“Difficulties in communicating with our customers’ employees and delivery delays due to COVID-19 may impact our ability to meet customer demand, and thus decrease revenue into 2021 and negatively impact our financial condition and results of operation,” reads an excerpt from the 10-K filing.

Thus, the trial order is seen as an opportunity for AmpliTech to demonstrate its capabilities on multiple fronts, including proving the forecasted inability to meet customer demand wrong and may well provide the impetus for a financial turnaround by opening AMPG up to an even larger order.

For more information, visit the company’s website at www.AmpliTechInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, May 21st, 2021 Uncategorized Comments Off on $AMPG New Trial Order among Positives That Could Drive Financial Turnaround

$PLTXF Enters Agreement to Acquire MKC’s Plant-Based New Deli

PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, announced that, through its wholly owned subsidiary, PlantX Lifestyle USA Inc., it has entered into an agreement to purchase all of the issued and outstanding membership interests of Matthew Kenney Cuisine Global LLC’s Planted-Based Deli LLC., known as New Deli. The agreement notes the purchase price will be $1,569,999. The California-based company is a sustainable, plant-based neighborhood bodega the offers customers practical, everyday options ranging from household supplies and personal hygiene products to frozen foods, pantry staples, snacks, beer and wine. In addition, New Deli customers can order coffee or plant-based, freshly prepared ready-to-go meal items designed by renown vegan chef and PlantX chief culinary officer Matthew Kenney. Founded with the mission to bring conscious, sustainable and healthy products to its community, New Deli’s purpose aligns with the vision for the PlantX brick-and-mortar locations currently under development. New Deli has reported year-over-year sequential growth in revenue and profitability, including a 1.75x increase in gross revenue based on Q1 2021 annualized compared to 2019 YE. “This new acquisition strengthens PlantX’s position as a leading plant-based company, while facilitating the company’s physical and e-commerce expansion across North America,” said PlantX CEO Julia Frank in the press release. “In addition to e-commerce, PlantX has always believed that an interactive one-stop-shop that consumers interested in plant-based living could visit, should be accessible throughout the United States and Canada — a void that New Deli by PlantXplans to fill.”

To view the full press release, visit https://ibn.fm/bM7wA

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor-plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. PlantX Life uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $PLTXF Enters Agreement to Acquire MKC’s Plant-Based New Deli

$XPHYF Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

  • XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health
  • The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe
  • In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East

In an interview on Proactive on March 22, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO and Director Hugh Rogers explained the implications of the CE-IVD approval (European certification) the company’s 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”) had just received. One notable remark was that this approval would facilitate the sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East, and North America (https://ibn.fm/RJWe5).

XPhyto, a life sciences technology accelerator, recently announced the delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel, signaling its entry into the Middle East, subject to commercial regulatory approval and subsequent potential product distribution (https://ibn.fm/2gS4J).

These units will be used for clinical evaluation based on the European CE-IVD approval, one of several international medical device certifications recognized by the Israeli government. The evaluation, expected to be completed within 90 days, will be conducted by the Medical Device Division of the Israeli Ministry of Health (“AMAR”).

“We are excited by the opportunity to expand potential distribution beyond Germany,” said Rogers. “We are building strong partnerships around the world, and Israel is a leading nation for COVID-19 management and research.”

One such partnership is with the Israeli distributor, which markets and distributes a range of medical products, including diagnostics, in Israel and surrounding countries. It has an extensive portfolio of customers in both the private and public sectors, such as the government, pharmacies, hospitals, and health care providers.

XPhyto is banking on the fact that rapid and accurate testing will undoubtedly continue being a vital tool for monitoring and managing the pandemic for many years to come. This is despite the successful rollout in various countries, including Israel. In fact, the Middle Eastern country had already vaccinated about 58.5% of its population as of April 13 (https://ibn.fm/m4auk).

Vaccines are not 100% effective in preventing COVID-19 infection. As such, vaccinated people should still undertake regular testing to lower the risk of spreading the disease, especially with the emergence of new, more lethal variants. Experts consider testing an indicator of where the disease is localized and to which areas it is spreading (https://ibn.fm/hYDWd). During the Proactive interview, Rogers had alluded to these facts.

“As vaccines roll out, it’s going to be inconsistent across jurisdictions for various logistical and economic reasons. So, you can expect testing at any border control (point), (before) international travel and even (when) monitoring the efficacy of the vaccine. You are looking at significant testing for several years,” Rogers noted.

This outlook has enabled XPhyto to expand distribution beyond Germany, where it has already signed a distribution agreement (https://ibn.fm/ZfJZA), potentially to other areas of the world. Seeing that the company is on track to actualize its plan to enter the Middle East, entry into the North American market may well be on the horizon.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $XPHYF Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

$WTER Announces A88CBD Partnership with Barstool Sports

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company, has teamed up again with Barstool Sports, a series of network podcasts. As part of the brand partnership, WTER’s A88CBD(TM) line will be featured on eight network podcasts, including Short Porch and Section 10; the brand will also be featured on the social media accounts related to the respective podcasts. WTER’s A88CBD brand sources, produces and refines industry-leading CBD (“CBD”) (cannabidiol) commodities designed to enrich the daily wellness routines of their customers. WTER is committed to creating quality, hemp-derived CBD products, with  CBD sourced from hemp that is lawfully grown and processed within the United States. The partnership between the two companies kicked off in April and included five shows that ran through May 2; the most recent announcement expands the dates from May 12 through June 17 and includes eight shows. Barstool Sports shows, including Short Porch, Section 10, and the other franchises, can be found on Spotify, Apple Podcast App, Google Play Store and more. “We are thrilled that our A88CBD product line is being featured on a number of the Barstool Sports franchises,” said The Alkaline Water Company  president and CEO Ricky Wright in the press release. “Barstool Sports has a large, engaged audience across their platforms, which is perfect for us to continue to raise brand awareness.”

To view the full press release, visit https://ibn.fm/H7K06

About The Alkaline Water Company Inc.

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. WTER’s flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. Quickly being recognized as a growing lifestyle brand, Alkaline88  launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the WTER’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products Inc. includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. For more information about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $WTER Announces A88CBD Partnership with Barstool Sports

$TOBAF Patent Filing Advanced to Nonprovisional Status

May 18, 2021
  • Advancement means patent examiner will be assigned to review filing
  • TAAT CEO notes that IP protection afforded by patent on Beyond Tobacco base material could improve company’s competitive position
  • The filing intended to protect proprietary refinement technique that characterizes both TAAT and its Beyond Tobacco base material

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) is a step closer to being the patent owner of a game-changing process that causes Beyond Tobacco(TM) to taste and smell much like the real thing. The company’s patent filing with the United States Patent and Trademark Office has been advanced to nonprovisional status, with the assignment of a patent examiner currently pending (https://ibn.fm/YVHfh).

“The intellectual property protection afforded by a patent on the Beyond Tobacco base material of TAAT(TM) could improve our competitive position in the tobacco industry,” said TAAT CEO Setti Coscarella. “Aside from the fact that it would be more difficult for competitors to imitate our product, it would be more practical for us to manufacture Beyond Tobacco using third-party producers instead of producing only in-house, which we currently do because the process is a trade secret. We are pleased to have advanced this process in line with standard timeframes for U.S. patent applications, and we look forward to undertaking the steps to finalize this patent, which we believe can strengthen TAAT as a competitive product and a uniquely better choice for smokers aged 21+.”

TAAT filed the original provisional patent in September 2020. The filing is intended to protect the company’s proprietary refinement technique that characterizes both TAAT and its Beyond Tobacco base material. The technique is at the center of the company’s ability to offer its flagship product. Available in Original, Smooth and Menthol, TAAT the product provides smokers with a tobacco-free and nicotine-free alternative that still offers the sensation of smoking.

TAAT was initially made available for retail sale throughout Ohio in October 2020; the innovative product was offered through TAAT’s online portal beginning in February 2021. Response to the product has been impressive with purchase orders steadily increasing and users reporting satisfaction with the product’s experiential similarity to that of smoking a tobacco cigarette.

“As the company continues its efforts to build market share in the $814 billion global tobacco industry, patents can play an important role in its ability to establish a market position and preserve the competitive advantages that can be had from patent protection,” the announcement noted. “Incumbent firms in the tobacco industry are among the world’s top patent filers, with Philip Morris International and Japan Tobacco International having been listed in the 100 Top Patent Filers by the European Patent Office in 2016 and 2019, respectively.

The next step for the company’s patent filing involves an examiner reviewing TAAT’s claims and potentially granting a United States patent based on the findings.

TAAT Lifestyle and Wellness has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry.

For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com.

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $TOBAF Patent Filing Advanced to Nonprovisional Status

$SRAX Sees Q1 Revenue Growth, Increases Full-Year Guidance

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (”SaaS”) platform, has released its Q1 financial numbers and operational highlights for the period ended March 31, 2021, In addition, based on positive numbers, the company increased its guidance for the year. Noteworthy numbers for first quarter include revenue up 1,450% over last year, reaching $5.4 million; Sequire bookings totaling $10 million for first quarter and already reaching $7.2 million in quarter two; and nine consecutive quarters of growth for Sequire. In addition, the company reported that 200 public companies had subscribed to Sequire, which is an increase of 17 since the fourth-quarter release. In addition, the company reported gross margins of 70% compared to 68% the same period last year and an EBITDAincrease of $2.6 million ($600K) vs. ($3.2 million) in the second quarter of 2020. “Our team has delivered another amazing quarter,” said SRAX founder and CEO Christopher Miglino. “We continue to see accelerated bookings. Our technology continues to deliver valuable results for our clients as we continue to add new features. We have a robust pipeline of features that will be added this year. The best of what we are building has not even hit the market yet.”

To view the full press release, visit https://ibn.fm/KQVrT

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $SRAX Sees Q1 Revenue Growth, Increases Full-Year Guidance

$RWBYF Releases Update on Management Cease Trade Order

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has announced an update on the status of a management cease trade order (“MCTO”) granted on May 3, 2021; the order was granted on May 3, 2021, by the British Columbia Securities Commission. The announcement noted that on that day, RWB noted it would be delayed in the filing of its financial statements and accompanying management’s discussion and analysis for the FY 2020, for the period ended Dec. 31, 2020; the delay was beyond the period prescribed under applicable Canadian securities laws. The company intends to file the requisite reports and statements for Q1 2021 on or about June 2, 2021. According to the announcement, the public will be able to continue to trade in the company’s listed common shares; the company’s CEO and chief financial officer, however, will not. The company also noted that it will issue biweekly status reports until it completes the annual filing requirement.

To view the full press release, visit https://ibn.fm/93VQI

About Red White & Bloom Brands Inc.

Red White & Bloom Brands is positioning itself to be one of the top-three, multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on major U.S. markets, including Florida, Illinois, California, Michigan, Oklahoma and Arizona, with respect to cannabis, as well as the United States and internationally for hemp-based CBD products. For more information about the company, please visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $RWBYF Releases Update on Management Cease Trade Order

$PBIO With Sales Up Over 120%, Pressure BioSciences to Host Q1 2021 Financial Results and Business Update on Wednesday, May 19, 2021

Q1 Financial Results Strongest Since Q4 2018; Q2 Revenue Already Exceeds Q2 2020.

Purchase of Accretive, Eco-Friendly Agrochemical Supplier Nearing Close.

SOUTH EASTON, MA / May 18, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its First Quarter 2021 financial results and provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a Company website link).

The teleconference will include a Company presentation followed by a Question & Answer period.

Date: Wednesday, May 19, 2021. Time: 4:30 PM Eastern Time (ET).

To attend this teleconference, live by telephone: Dial-in (877)-407-8033 (North America); 201-689-8033 (International). Verbal Passcode: PBI Q1 2021 Financial Call and Business Update.

For those unable to participate in the live teleconference, a replay will be available beginning Thursday, May 20, 2021. The replay will be accessible via telephone and the Company’s website for 30 days. Replay Number: (877)-481-4010 (North America); (919) 882-2331 (Int’l); Replay Passcode: 41416.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (T) (508) 230-1828
Jeffrey N. Peterson, Chairman of the Board (F) 508-230-1829

Tuesday, May 18th, 2021 Uncategorized Comments Off on $PBIO With Sales Up Over 120%, Pressure BioSciences to Host Q1 2021 Financial Results and Business Update on Wednesday, May 19, 2021

$POAI Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and public data together with active learning. “What this platform does is it’s a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines, like doing, if you will, a clinical trial in a plastic dish,” said Collins. “Because we have all these patient cell lines that we have knowledge of . . .  what drug they were treated with and so on. And we believe this will revolutionize the way that pharma does drug discovery.”

To view the full article, visit: https://ibn.fm/LwON7

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $POAI Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

$NEXCF to Acquire Silicon Valley-Based Threedy.ai Inc.

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, has announced its entry into a binding letter of intent (“LOI”) dated May 14, 2021, with Threedy.ai Inc. to acquire all outstanding shares of Threedy. Threedy is an artificial intelligence (“AI”) company based in Silicon Valley, California, backed by prominent venture capitalists (“VCs”) and investors. The company has an expansive list of clients, including Walmart, Wayfair, Kohl’s, Pier 1 Imports, and many more, and has been building AI technologies for the 3D model creation of physical products at scale. “I have been patiently waiting for a company to come along that not only understands AI but also understands that AI is the key to cracking the code on scaling AR content creation,” said Evan Gappelberg, CEO of Nextech. “Nima and Max are two rare entrepreneurs who have figured it out and are gutsy and smart enough to not only build their disruptive technology but also bring it to market through the world’s largest retailers. With Threedy’s technology and Nextech’s global sales and marketing machine, our combined AI teams and our existing AR tech and resources as a public company, I’m convinced that we will quickly take a leadership position in the AR industry.”

To view the full press release, visit https://ibn.fm/hvwcF

About Nextech AR Solutions Corp.

Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences, altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences. Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three ecommerce platforms, VacuumCleanerMarket.com (“VCM”), InfinitePetLife.com (“IPL”) and TruLyfeSupplements.com (“TruLyfe”), as well as VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, visit www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $NEXCF to Acquire Silicon Valley-Based Threedy.ai Inc.

$NETE Releases Q1 2021 Financial Report, Provides Update on Pending Merger

Net Element (NASDAQ: NETE)a financial technology company in the process of becoming a pure-play electric vehicle (“EV”) manufacturer through a pending definitive agreement with privately held Mullen Automotive Inc., has reported its financial results for the quarter ended March 31, 2021; the report also included an update for shareholders on its previously announced merger with Mullen, a Southern California-based electric vehicle (“EV”) company. The merger is a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company. Financial numbers for the quarter included net income attributable to common stockholders of approximately $0.3 million or $0.05 per share income compared to a net loss of approximately $1.4 million or $0.33 per share loss for the same period in 2020. The company reported that the decrease in net loss was primarily due to an increase in net revenues and approximately $1 million in late fees owed by Mullen. “We are pleased to report that we filed a Form S-4 registration statement with the SEC on May 14, 2021, a milestone furtherance of the proposed merger with Mullen,” said Net Element executive chair Oleg Firer in the press release. “We want to thank our shareholders for their patience through this process, and we will continue working diligently to conclude the transaction as soon as regulatory and stockholder approvals are received.”

To view the full press release, visit https://ibn.fm/bivzL

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. For additional information, visit www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $NETE Releases Q1 2021 Financial Report, Provides Update on Pending Merger

$IDEX Releases Q1 2021 Financial Report

Ideanomics (NASDAQ: IDEX), a global company focused on driving the adoption of commercial electric vehicles and associated energy consumption, has reported its financial numbers for Q1 2021. Included in the report was revenue of $32.7 million, which represents the fifth consecutive quarter of growth, and gross profit of $10.8 million for the period ended March 21, 2021. The company noted that the first-quarter numbers included first revenues from its two January 2021 acquisitions: WAVE, an inductive-charging business, and Timios, a title and escrow services company. Corporate highlights for the quarter included the company’s acquisition of WAVE and Timios, as well as its announced sponsorship in NACFE and membership in CALSTART. The company also noted that Timios generated record-high revenue for the quarter as it  expanded its retail purchasing business. The company reported that it ended the quarter with $356 million cash, which provides a deep pool of capital for continued investment in its mobility and capital business units. “Ideanomics is transforming dramatically quarter over quarter,” said Ideanomics CEO Alf Poor in the press release. “I am both pleased and proud to say that as is stands today the company is the healthiest it has been in close to three years that I have been on board.”

To view the full press release, visit https://ibn.fm/LJ5XE

About Ideanomics

Ideanomics is a catalyst for disruption to those industries where improvements in sustainability, transparency and freedom of choice would have profound benefits on a global scale. The company’s Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy-management solutions under an innovative sales to financing to charging (S2F2C) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, the Mobility & Capital divisions provide Ideanomics’ global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and its shareholders with the opportunity to participate in high-potential growth industries. The company is headquartered in New York City with operations in the United States, China, Ukraine and Malaysia . For more information about the company, please visit www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $IDEX Releases Q1 2021 Financial Report

$HWAL What to Watch in Second Surge for NFT Stocks

The NFT space may ultimately prove to be the “most important thing about the crypto revolution” over time. It has already emerged as one of the most interesting trends across markets in 2021.

The question that arises in the wake of this interest is: Is this all just a fad – a short-lived craze that has no serious staying power or important role in the economy of the future?

We would suggest one read recent work from thought leader Jesse Walden of Variant Fund, who put out an eloquent exploration of the NFT boom ahead in his piece “NFTs Make the Internet Ownable”.

The gist of the piece is that NFTs make the rest of the economy ownable – seeing as how everything but shared digital assets was already ownable before the rise of the NFT concept.

The addition thus provided is a huge one: all photography, art, music, journalism, and literature occurring online is basically in this territory. It’s more or less the whole of the content universe we consume each day.

And it’s actually so much more than that because it also represents individual pieces of other larger content assets that were already owned but can now be pieced off and auctioned to create separate value, including iconic sports highlights, historic interview clips, astounding live performances, and other “moments” of culture.

But that isn’t the whole picture. Once we have established this new mechanism for value assignment, whole industries will emerge or mature around that concept to capitalize on it. At the end of the day, this is likely to be far from a short-lived craze.

Given that view, we would suggest taking a closer look at some of the stocks in the NFT space, including Plby Group Inc (NASDAQ:PLBY), Hollywall Entertainment Inc (OTCMKTS:HWAL), and Oriental Culture Holding Ltd (NASDAQ:OCG).

 

PLBY Group Inc (NASDAQ:PLBY) frames itself as a company that connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four major categories: Sexual Wellness, Style & Apparel, Gaming & Lifestyle, and Beauty & Grooming.

PLBY Group’s flagship consumer brand, Playboy, is one of the most recognizable, iconic brands in the world, driving billions of dollars in consumer spending annually across 180 countries.

PLBY most recently announced recent financial performance data, including revenue growth of 34% year-over-year to $42.7 million, driven by 114% growth in direct-to-consumer revenue in the comparable period, a net loss of $5.0 million, largely due to a $13.8 million year-over-year increase in selling and administrative expenses, and adjusted EBITDA of $6.7 million, burdened by an additional $1.5 million of one-time expenses related to M&A transaction expenses, severance, and COVID testing at the Company’s fulfillment center, none of which were added back to arrive at adjusted EBITDA.

Ben Kohn, Chief Executive Officer of PLBY Group, stated that he was “thrilled by the recent performance of our first NFT art drop, a symbol of the infinite product experiences we can build off the back of our iconic flagship brand and rich archive. We are in the early innings of unlocking the tremendous potential of our intellectual property and global fan base and remain focused on investing today in opportunities to drive superior long-term growth and deliver substantial long-term value for our shareholders.”

Even in light of this news, PLBY hasn’t really done much of anything over the past week, with shares logging no net movement over that period. Shares of the stock have powered higher over the past month, rallying roughly 42% in that time on strong overall action.

 

Hollywall Entertainment Inc (OTCMKTS:HWAL) is a diversified player with active commercial interests in multiple fast-growing industries and ties to major themes including 5g infrastructure, internet-of-things, and proprietary high-value entertainment assets.

In a recent company communication, HWAL was described as a company with a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media, and entertainment.

However, for our purposes today, the real topic is HWAL’s music rights portfolio, which was recently valued at nearly $150 million. This basket of legends includes the rights to manufacture and distribute over 17,500 master recordings performed by such legends as Ray Charles, Ella Fitzgerald, The Jackson 5, Frank Sinatra, Dolly Parton, Elvis Presley, Tony Bennett, The Bee Gees, Chicago, Platters, George Gershwin, Marvin Gaye, James Brown, Nat King Cole, John Lee Hooker, Willie Nelson, Rod Stewart, Hall and Oates, James Taylor, Etta James, Aretha Franklin and many other multiple platinum selling acts.

Hollywall Music Library has been preserved for over 20 years and contains some of the rarest and most coveted unpublished recordings from countless Legendary Music Recording Artists. The company is now taking this further and developing a one-of-a-kind, state of the art, digital distribution and verification system- designed to maximize customer delivery, quality control, and revenues for artists, writers, content developers, copyright owners and shareholders.

Hollywall Entertainment shares have pulled back to key support in the $2/share area, where the stock has found stable buying interest to give it support over the past two months. That forms a potentially important technical basing pattern that could be triggered by an upside breakout if momentum in the NFT theme re-emerges.

 

Oriental Culture Holding LTD (NASDAQ:OCG) trumpets itself as an online provider of collectibles and artwork e-commerce services, which allow collectors, artists, art dealers and owners to access an art trading market with a wider range of collectibles and artwork investors.

Through its subsidiaries in Hong Kong, the Company provides trading facilitation for individual and institutional customers of all kinds of collectibles, artworks and certain commodities on its online platforms, as well as online and offline integrated marketing, storage and technical maintenance service to customers in China.

OCG most recently announced its financial results for the fiscal year ended December 31, 2020, including operating revenues up by $4.0 million (or 29.7%) year-over-year to $17.4 million, gross profit at $14.8 million in 2020 as compared to $12.1 million in 2019, representing a 22.1% growth from the same period in 2019, and net income at $2.0 million in 2020, a decline of $7.1 million or 77.5% from $9.1 million in the same period of 2019.

Mr. Lewis Wan, Chairman of the Board of Directors of the Company commented, “As Covid-19 vaccines become available to wider community in the world, we believe a global economic recovery in 2021 is around the corner. With quantitative easing and low interest rate, capital flow and world economy will likely head for a change. We believe that as money pours into the market as a common tool to stimulate economic growth, the scarcest asset will not be cash but real, liquid assets, especially those are valued in RMB considering the growth in China. The products traded on OCG’s platforms are both valued in RMB, and are liquid assets that worth investing in with high collection values.”

Even in light of this news, OCG has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby, and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -7%.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $HWAL What to Watch in Second Surge for NFT Stocks

$CBDHF Releases First-Quarter 2021 Financial Report

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), an industry leader in full-spectrum cannabidiol (“CBD”) hemp-extract wellness products and probiotics, announced its Q1 financial results, for the period ended March 31, 2021. Highlights from the report include consolidated revenue for the company totaling $983,496, an increase of 7.6% over the $913,646 reported in fourth-quarter 2020; DTC sales up 59.3% from Q4 2020, totaling $244,255 as compared to $153,305; B2B net revenue decreased 2.8% to $739,241 from 760,341 in fourth-quarter 2020 with international sales, which totaled $75,994, up from no sales in Q4 2020; and gross profit of $280,205, or 28.5% of net revenue. The company also reported a 42.9% increase in operating expenses, which totaled $6,306,703; the increase was primarily attributed to IPO- (“IPO”), marketing- and digital-related expenses. The company ended the quarter in a strong cash position, holding $17,074,030. In addition, HempFusion pointed to several business highlights in the report, including the completion of a $17 million initial public offering and the commencement of trading its stock on the Toronto Stock Exchange (“TSX”), marking the first time a U.S.-based CBD and wellness products company listed directly on the TSX. The company also launched its Probulin store on Amazon and became the no. 2 most recognized CBD brand in America according to Brightfield Group. “With nearly all international business paused due to COVID throughout 2020 and Q1 2021, and with slower than expected reopenings, the company still achieved an incremental QoQ growth of 7.6%,” said HempFusion co-founder and CEO Jason Mitchell, ND, in the press release. “Now, with vaccine rollouts taking place across the country, we are encouraged with reopening rates and excited that our sales, which currently take place in approximately 75% brick-and-mortar businesses, are beginning to reopen. We remain committed to developing new revenue channels and have entered additional countries including China, Ireland, and the United Kingdom, and we are excited with subsequent quarterly events in which new purchase orders were received, showing early signs of the return of international business. These international POs have the potential to drive millions in revenue.”

To view the full press release, visit https://ibn.fm/SPbeS

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in stores or online. For more information about the company, visit www.HempFusion.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at http://ibn.fm/HempFusion

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $CBDHF Releases First-Quarter 2021 Financial Report

$FNGR Announces Successful Negotiation of Contract with China Mobile Fujian

FingerMotion (OTCQX: FNGR), a mobile data and services company, has entered into a  volume-based contract with China Mobile Fujian. The company anticipates that the contract will show an approximate 30% improvement in gross margin on its SMS business. FingerMotion, along with its subsidiary, JiuGe, has been working for years on this collaboration, with the end result of offering high-quality service to the end user. China Mobile Fujian currently has an estimated 70% of the market in the province of Fujian, which is approximately 30 million or more online subscribers. The agreement represents FingerMotion’s commitment to continuously enhancing its platform, resulting in positive customer response rates and distinguishing itself from other competitors. “Our focus over the past year was on improving margins,” said FingerMotion CEO Martin Shen in the press release. “This volume-based agreement is expected to increase our margins from 6.1% to approximately 30% and is a testament to our incredibly talented team that continues to impress our business partners. With SMS demand remaining strong, we are able to meet the new pressures through operational efficiencies but continue to be limited by the capital required to adequately fund operations. In addition to this expected increase in gross margin, we also expect the top-up revenue growth to dramatically accelerate in the next quarter and through the rest of our fiscal year ended February 28, 2022. With the forthcoming arrival of two exciting new business segments in insuretech and 5G, and their corresponding revenues, we want to assure our shareholders that are working diligently towards positive earnings this year.”

To view the full press release, visit https://ibn.fm/oy4sv

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position FingerMotion to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and expand the model to other regional markets. For more information about the company, visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $FNGR Announces Successful Negotiation of Contract with China Mobile Fujian

$UUUU Hosts Q1 2021 Earnings Call

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company, at 4:00 p.m. ET on May 17, 2021, hosted a conference call to discuss its earnings results for the first quarter of 2021. Interested parties should visit https://ibn.fm/qsg1W to access a replay of the call.

To view the full press release, visit https://ibn.fm/n6qM6

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $UUUU Hosts Q1 2021 Earnings Call

$CLXPF Wall Street Unicorns in Process of Changing the Healthcare Landscape

NetworkNewsWire Editorial Coverage: Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and MDMA (methylenedioxymethamphetamine) — and then the Controlled Substance Act was signed into law, which labeled those substances as drugs of abuse with no medical value. The severely limited research conducted thereafter continued to demonstrate the potential of these compounds to provide therapeutic value, particularly for notoriously difficult diseases such as depression, addiction, PTSD and others. In the past few years, the relatively unattended field of psychedelic therapeutics is seeing a revival of activity and excitement, spawning innovative approaches and creating valuable companies in the process. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) is one of the exciting new companies to enter the public domain, bringing a diversified pipeline and de-risked strategy that should usher the company right into phase 2 clinical trials. A public company since its IPO in December of 2020, Tryp aims to become a leader in the healthcare and drug development industries alongside others, including COMPASS Pathways Plc (NASDAQ: CMPS)Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP)Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF)Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED).

  • Psychedelic therapeutics research is on the rise with a few companies standing out in a market forecast for 12.36% CAGR to reach $10.75 billion by 2027.
  • Tryp is led by pharmaceutical experts with backgrounds in drug development utilizing FDA regulatory pathways.
  • Tryp’s primary indications are fibromyalgia and eating disorders using its proprietary psilocybin formulation.
  • Tryp’s pipeline is diversified, including non-psychedelic drugs like Razoxane, which is in development for soft tissue sarcomas.

Goodbye Stigma, Welcome New Generation in Healthcare

Most people may not recognize some of the medical terms for psychedelics, but nearly all know their street names, including magic mushrooms, ecstasy, Molly and LSD. Over decades, people have been conditioned to the stigma of these illicit substances, instigated and promoted by the Controlled Substances Act. However, the negative stigma is being lifted and being replaced by a growing body of scientific clinical evidence that strongly suggests psychedelics may well become one of the greatest advancements in mental health and neuropsychiatric disease in decades.

The mounting evidence of therapeutic value in psychedelics is following a similar path as medical cannabis, with pockets of decriminalization emerging in cities first with states following, as Oregon became the first state to legalize medical psilocybin (the active ingredient in magic mushrooms) in November. Likely just the start of a wave of acceptance and medicinal use, ResearchandMarkets.com forecasts 12.36% compound annual growth for the psychedelics drug market and expects the market to reach nearly $11 billion by 2027.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) offers a best-in-class, drug development team capable of taking compounds from early stage and advancing them through the rigors of clinical development to commercialization. This team of executives and advisors cannot go understated as it’s made up of deep experience and key leadership positions throughout, including large pharma, emerging pharma, drug approvals, psychedelics and capital markets.

Tryp will certainly benefit from the continued clinical research and data being collected on psychedelics to treat mental health, which further legitimizes efficacy. However, Tryp is not immediately focused on treating depression or PTSD like many other companies operating in the space. Management has the company uniquely positioned by recognizing blockbuster opportunities that exist in other indications with large unmet medical need that could potentially be treated with psilocybin including fibromyalgia and binge eating. Furthermore, Tryp has differentiated itself with a diversified pipeline that also includes a well-understood oral drug the company plans to develop for soft-tissue sarcomas.

Differentiated Indications and the Advantages of 505(b)(2)

Tryp’s multidimensional pipeline consists of its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program and Razoxane (TRP-1001) for soft-tissue sarcomas. The lead drug in the PFN program is TRP-8802, a synthetic, oral psilocybin medication initially being used to treat fibromyalgia, a condition of chronic widespread pain with no known cause.

Tryp is also collaborating with University of Florida’s Jennifer Miller, M.D. to initiate a clinical trial of TRP-8802 to treat the symptoms associated with certain eating disorders. In both cases, Tryp will be pursuing the FDA 505(b)(2) pathway to bypass preclinical and Phase I studies and move directly into Phase 2 clinical trials. The 505(b)(2) pathway is a streamlined process that allows drug developers to utilize work done by others to demonstrate the safety of a particular active ingredient. Relying on existing data eliminates unnecessary duplication of research and can save a company millions of dollars and years of studies compared to traditional pathways.

This is also the pathway Tryp will be seeking for TRP-1001 for soft-tissue sarcomas (“STS”). Razoxane belongs to the family of bis-dioxopiperazines, developed in the 1960s as derivatives of the chelating agent EDTA. As such, Tryp has decades of research to underpin and accelerate its development of TRP-1001 in a novel process.

Orphan Drugs, Large-Market Opportunities

Tryp is taking advantage of this accelerated regulatory pathway to develop treatments for both highly prevalent as well as rare diseases.  Fibromyalgia is a condition of chronic widespread pain that impacts 6 to 12 million Americans annually with no known cause. Common treatments include muscle relaxants, antidepressants, anticonvulsants and anti-inflammatory drugs. This is a $3.6 billion market ripe for disruption as a new drug hasn’t been approved in over a decade.

Eating disorders are a tremendous market opportunity considering more than 30 million Americans will suffer from one. Tryp’s study at the University of Florida will also include hypothalamic obesity.

“Orphan” indications are rare diseases with few treatment options that affect fewer than 200,000 persons in the United States. Receiving an FDA orphan drug designation provides a bevy of incentives to a drug developer including expedited review processes, tax credits, extended period of exclusivity and waived fees, among others. Worldwide orphan-drug sales are forecast to make up 20% of the total prescription market in 2024 with sales reaching $242 billion.

Soft-tissue sarcomas (“STS”) is another orphan indication opportunity for Tryp. About 13,460 new soft-tissue sarcomas will be diagnosed, and it is estimated that 5,350 people will die of soft tissue sarcomas this year.  The disease also comprises 7% of all cancer diagnosis in children.

World-Class Development Team

Gregory McKee recently came on as CEO and executive chairman at Tryp, bringing more than two decades of biotechnology, life-sciences-management and venture-investment experience to the company after filling executive positions with Torrent Ventures, CONNECT, Nventa Biopharma (merged with Akela Pharma) and Genzyme (acquired by Sanofi for $22 billion). Tryp co-founder and director James Kuo, MD, has extensive experience garnered from Pfizer, Discovery Labs, Myriad Genetics and as current chairman of ImmunoPrecise. President and chief science officer James Gilligan, PhD, brings 35 years of life-sciences experience to Tryp after co-founding Unigene Laboratories and the Bracken Group.

It is nearly impossible to adequately cover the entire Tryp C-suite, board and advisory team, all of which boast resumes similar to the aforementioned. Key members of Tryp management have held top executive positions and leadership roles at companies such as Pfizer, QLT, ImmunoPrecise Antibodies and many more. COO Tom D’Orazio has taken two cancer drugs through the Health Canada approval process. Vice president of manufacturing Larry Norder led chemistry aspects of early-stage R&D, preclinical and clinical developments for the blockbuster Naproxen. The impressive list goes on and on.

The company also recently added Dr. Robin Carhart-Harris, one of the world’s foremost experts in administration of psychedelic compounds, to its Scientific Advisory Board (“SAB”); Dr. Joel Castellanos and Dr. William Schmidt, both leading experts in drug development for chronic pain, also joined the company’s SAB earlier this year.

Tryp has attracted a team of luminaries and is on a collective mission to provide relief for serious medical conditions that have plagued the populace far too long without enough effective solutions. A team of this caliber may well be the answer to overcoming the magnitude of the problem.

Wall Street Wants In

The psychedelic revolution has begun. The evidence is everywhere. Venerable organizations like Johns Hopkins University and Imperial College of London are leading the charge and lending ever more credence to the safety and efficacy of therapeutic psychedelics. New venture firms are cropping up to pour cash into the space. Non-profit MAPS, the Multidisciplinary Association for Psychedelic Studies, late in 2020 raised $30 million from donors to conduct a Phase 3 clinical trial for PTSD using MDMA-assisted psychotherapy and recently reported positive results from the trial.

COMPASS Pathways Plc (NASDAQ: CMPS) was one of the first unicorns (companies with a $1 billion valuation) in the psychedelics space. The London-based company is developing a synthetic psilocybin (COMP360) administered in conjunction with psychological support for treatment-resistant depression, which has earned a vaunted breakthrough therapy designation from the FDA. COMPASS expects to have data from a phase 2b clinical trial for this indication by the end of 2021.

Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP) is taking a different approach as a leader in the development and delivery of psychedelic therapies. Its Field Trip Discovery division is working on the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi. Its Field Trip Health division is building centers for psychedelic therapies. The company this month opened its fifth location in the United States, with construction commencing in other U.S. and Canadian cities.

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) recently disclosed that it will be targeting Alcohol Use Disorder as the initial indication for its proprietary deuterated psychedelic tryptamine, CYB003, which is being developed in collaboration with NYSE-listed Catalent. The company has four psychedelics in its pipeline, including CYB001, which is planned to be evaluated as a sublingually administered version of psilocybin in Phase 2a and 2b clinical trials for Major Depressive Disorder.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) is developing a diverse pipeline of psychedelic substances, including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative called 18-MC. MindMed, which also has a valuation over $1 billion, last month graduated from the OTC to the NASDAQ, joining COMPASS as one of the few big-board listed psychedelic companies. This month, MindMed announced Project Angie, a new program where it will begin looking at LSD to treat pain conditions.

Those looking for innovation in healthcare are seeing it unfold before their eyes today. The excitement for therapeutic psychedelics is reaching a fever pitch as investors, academia, and scientists alike are all starting to realize the potential for psychedelics to change the healthcare landscape.

For more information about Tryp Therapeutics, please visit Tryp Therapeutics.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $CLXPF Wall Street Unicorns in Process of Changing the Healthcare Landscape

$CNSP Leukemia Treatment Could Lie in Avocado Compound

Like many other types of cancer, leukemia currently has no cure. Although treatments are largely dependent on whether the cancer is slow growing or aggressive, most of the treatments are pretty toxic and, in extreme cases, can even cost the patients their lives. There are several types of leukemia, and researchers from the University of Guelph may have found a way to cure one of the most devastating forms of cancer, acute myeloid leukemia (“AML”).

AML often afflicts people over the age of 65 and has quite a low survival rate; less than 10% of patients live for more than five years once they are diagnosed with the life-threatening condition. According to a new study from the University of Guelph in Canada, a compound found in avocados may offer a safer and more effective treatment for acute myeloid leukemia. For the first time, scientists have identified an enzyme that is crucial for cancer cell growth, and the avocado compound targets and attacks this enzyme, says Dr. Paul Slagnuolo from the University of Waterloo in Ontario.

Called VL-CAD, this enzyme occurs in much higher amounts in leukemia cells. Cancer cells rely on the enzyme to survive, Spagnuolo says, but he and his colleagues found that avocatin B, a compound found in avocados, provides a promising treatment for AML. Avocatin B has the ability to target and destroy cancer cells while ignoring otherwise healthy blood cells, making it more effective and less toxic than other treatments used to alleviate the condition.

Spagnuolo and his team discovered avocatin B while screening nutraceutical compounds to find a compound capable of inhibiting VL-CAD. Consequently, the researchers have partnered with the Center for Commercialization of Regenerative Medicine (“CCRM”) in Canada to file a patent for using the avocado-derived compound to treat acute myeloid leukemia. However, Spagnuolo and his team acknowledge that it will take several years before avocatin B is used to treat AML in clinical settings.

Despite looking at several years of work before the compound can hit the shelves as a tried and tested treatment, Spagnuolo says this is quite an exciting time for his lab. He and his colleagues are one of few research teams in the world looking into nutraceuticals and applying intense drug-investigation processes to determine how they can be effective. If clinical trials are successful, patients suffering from acute myeloid leukemia will finally have a safe and effective means of treatment.

A lot of effort is going into cancer research, which includes myriad issues that need to be addressed. Many different companies, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are focused on a segment of the broad fight against cancer.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $CNSP Leukemia Treatment Could Lie in Avocado Compound

$BRSF Featured in Med-Tech News as Technology Provider Revolutionizing Pediatric Brain Diagnostics

  • BRSF featured in industry publication as a company that transforms EEG testing in children, cutting procedure time from 30 to as little as 5 minutes.
  • The need for brain diagnostics in children is on the rise, but supply and availability of EEG testing to pediatric physicians remains limited.
  • BRSF has stepped in to fill the gap in unmet patients’ needs; positioning itself as a leading innovator in this field.

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in Med-Tech News, a publication covering medical devices medical manufacturing, as a Company revolutionizing the space of pediatric brain diagnostics (https://ibn.fm/Aslgm). The feature piece authored by Irina Nazarova, marketing director of Brain Scientific, brings to attention the importance of having a new generation of devices for neurological diagnostics in children and why Brain Scientific’s solution is responding to this growing but still largely unmet patient need.

Often left under the radar of technology providers working in neurological diagnostics, the pediatric market also has a need for EEG devices because children can suffer from a number of neurological disorders, including seizures, sleep issues, brain infections and epilepsy. For example, epilepsy as one of the most common neurological disorders in children could lead to dangerous seizures if left undetected. Still, this list of possible pediatric applications of brain diagnostic devices is not exhaustive — it is constantly expanding with new conditions where the novel technology can make a difference for children’s health. For example, EEG testing could also be used for diagnosing ADHD, another growing market need as the article cites Child and Adolescent Psychiatry which reports that children with the disorder make up 42% of all children in the country. It could also be crucial for diagnosing autism, another prevalent condition challenging to diagnose, especially in younger pediatric patients.

Still, despite the apparent unmet need in patient care, the supply and availability of EEG testing to pediatric physicians are limited. That was before Brain Scientific stepped up to the challenge. The article describes how the Company responded with agility to feel the gap and establish a new innovative norm for pediatric clinicians.

After showcasing adult-sized NeuroCap at several medical technology conferences, Brain Scientific was approached by many attendees inquiring if the Company has a pediatric version already available or at least in development. Committed to unveiling emerging market needs and quick to respond to them, Brain Scientific started working to respond to this challenge right away. After plenty of consultations between the Company’s in-house team of specialists and the manufacturers and the medical testers to secure high-quality products, the NeuroCap for children was born — an easy-to-use disposable headset overcoming the infection risk and inconvenience burden of traditional EEG pediatric products.

Nazarova continues explaining that the pediatric version of NeuroCap comes with all the benefits of the adult version. Unlike most EEGs, which require a special technician to conduct the testing with a single machine, one patient at a time, pediatric NeuroCap is a pre-gelled hospital-grade children-size EEG headset that any member of clinical staff can apply. Like the adult edition, the pediatric NeuroCap is quick, disposable, sanitary and comfortable, transforming once tedious process that could take up to 30 minutes per child into a painless and simple routine for medical staff. Illustrating how the pediatric NeuroCap is a game-changer for EEG testing in children, the article reports that this novel device can conduct testing in as little as five minutes, delivering prompt test results. This makes it an excellent fit for pediatric patients in emergency rooms, ICUs, and clinics.

Despite the pandemic-related supply chain challenges, Nazarova concludes that Brain Scientific continues to be committed to help better equip healthcare facilities across the country. NeuroCap for children will join the Company’s proprietary lineup of diagnostic devices to bring affordable, easy-to-use brain diagnostics solutions for children.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $BRSF Featured in Med-Tech News as Technology Provider Revolutionizing Pediatric Brain Diagnostics

$AMPG Announces Q1 Results and Positioning to Participate in Hyper-Growth Opportunities

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art communications components for satellite communications, space, telecom and defense markets, today released financial results for the first quarter of 2021 (“Q1’21”) and reviewed its outlook for Q2’21 and beyond. Among the recent highlights, the company reported record Q1 bookings and a record backlog of $2.4M at close of Q1’21. “Our Q1 results continued to be negatively affected by the COVID-19 pandemic’s impact on the planning and procurement process of high-tech research and corporate organizations, resulting in a temporary reduction in demand for our products and services. Fortunately, we are already beginning to see a reopening of our markets and expect this to progress gradually as the year unfolds. We expect this trend to benefit AmpliTech going forward, along with potential pent-up demand for solutions in 5G, satellite, cyber security, quantum computing and other markets that have developed over the past year,” said AMPG president, CTO and CEO Fawad Maqbool. “AmpliTech has a track record of developing and launching industry benchmark products on accelerated timelines and at more attractive pricing than is possible by our competitors, many of which are very large and diversified. During the past year of COVID-19 related constraints across the industries we serve, we focused our strategy and team on new product development and positioning our company to participate in hyper-growth opportunities presented in satellite communications, the build out of true 5G infrastructure, as well as quantum computing and deep space exploration.”

To view the full press release, visit https://ibn.fm/YcjT1

About AmpliTech Group Inc.

AmpliTech Group designs, develops and manufactures custom and standard state-of-the-art RF components for the domestic and international, SATCOM, space, defense and military markets. These designs cover the frequency range from 50 kHz to 40 GHz — eventually offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or system design problems. The company’s steady growth over the past 13-plus years is driven based on its ability to provide complex, custom solutions for nearly any requirements. In addition, AmpliTech has the best assemblers, wires and technicians in the industry and can provide contract assembly of customers’ own designs. For more information about the company, visit www.AmpliTechinc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at http://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, May 18th, 2021 Uncategorized Comments Off on $AMPG Announces Q1 Results and Positioning to Participate in Hyper-Growth Opportunities

$XPHYF Texas House Passes Psychedelics Research Law

The House of Representatives in Texas passed a bill last week that would mandate the state to undertake research regarding the potential of different psychedelic substances, such as MDMA and psilocybin. The bill, whose chief sponsor was Rep. Alex Dominguez, a Democrat, was supported by 134 House members while 12 opposed it. The passage of the bill now means it heads to the state Senate for consideration.

During an earlier Public Health House Committee meeting, legislators modified the scope of this expected research to cover only military veterans suffering from PTSD rather than leaving the bill with its previously wide scope encompassing many other conditions impacting veterans.

While speaking on the floor of the House, Dominguez commented that the country loses approximately 6,000 military veterans annually, with the toll totaling 114,000 since 2001. All these gallant men and women are lost to suicide and PTSD, he added.

His bill was intended to take a step towards addressing such a huge cause of fatalities, and he hoped that Texas would send a strong message to federal authorities in Washington that more serious action needs to be taken to save the lives of military veterans.

The bill passed by the House will compel the state, in partnership with Baylor College and a health facility that specializes in treating veterans, to conduct a study to ascertain the medical benefits as well as the risks associated with the therapeutic use of ketamine, MDMA and psilocybin for the treatment of veterans. The bill also asks the Health Department to review the available literature on those three substances in addition to undertaking a clinical study of the use of psilocybin to manage PTSD in veterans.

As such a study is conducted, the Health & Human Services Department would be expected to table quarterly reports regarding its findings, and a final report on the matter is due, according to the bill, by the end of 2024. Rick Perry, a former governor of Texas, earlier on urged the lawmakers to pass this bill.

There are concerns that the Republican-dominated senate could block the passage of the bill or even water it down so much that it will hardly serve the objectives the members of the lower House who passed that law had in mind.

Texas’s Lt. Governor Dan Patrick is opposed to any law that relaxes the state’s restrictions on drugs, and there are fears that he could singlehandedly stall the bill since he presides over the senate. All eyes are now on the senate to see what happens next.

As different jurisdictions such as Texas move to pass laws easing research into psychedelics, private entities such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are signing agreements with partners to do research and development in this exciting industry that promises remedies to conditions which seem particularly hard to treat, especially mental health ailments.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, May 17th, 2021 Uncategorized Comments Off on $XPHYF Texas House Passes Psychedelics Research Law

$SRAX Sequire Marks 5M Retail Investors, Hosts LD Micro Invitational

May 17, 2021
  • Retail investors are more important now than ever, making Sequire a powerful tool
  • Data on who investors are, what they invest in is valuable asset
  • SRAX plans on creating even more value to platform through development of Sequire Investor Community

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced that Sequire, its proprietary SaaS platform, has reached a significant milestone — 5 million retail investors (https://ibn.fm/CsE8n).

“Retail investors are more important now than ever, as they have been driving the market, and companies are starting to pay attention,” said SRAX founder and CEO Christopher Miglino. “Data on who investors are and what they invest in is a valuable asset to every public company. This data provides us deep insights into trends and movements of all types of investors.”

SRAX’s Sequire platform is an operating system that publicly traded companies use to, first, track their shareholders’ behaviors and trends and then, based on the insights they gather from that data, engage current and potential investors across marketing channels. Sequire was officially announced in May 2020 as a rebrand of SRAX’s investor intelligence platform (https://ibn.fm/bJE68).

The name — Sequire — captures the platform’s main objective to both acquire and secure investors for publicly traded companies. “We are thrilled to announce the new brand, giving the platform its own identity separate from SRAX,” said Miglino. “It’s also arriving at an opportune time as we are developing new intelligent technologies to further provide public companies the tools to reach and engage their shareholders.”

The appeal of the platform seems evident as the community has grown to reach a network of more than 5 million influential, forward-thinking investors in barely a year; the Company plans on creating even more value through the development of the Sequire Investor Community. The Sequire Investor Community is a place where investors can convene, learn and share on a wide range of industry-related topics, the Company noted. More opportunities, education and news within this network will accompany the multiple investor events already slated for this year.

One of those events is the 2021 LD Micro Invitational, available via the Sequire virtual events platform and slated for June 8–10, 2021 (https://ibn.fm/gYldT). The premier, three-day virtual investor conference has gained a reputation for being one of the most influential conferences in the small-cap space.

An event designed specifically for newcomers and companies on the “cusp” of doing big things, the invitational is expected to include an estimated 180 companies; each company will offer a 25-minute presentation. In addition, this year’s agenda features several leading keynote speakers and a one-time attraction: the LD Micro Hall of Fame, which will include the top 50 companies out of the nearly 2,000 that have attended LD Micro events through the years.

SRAX, based in Los Angeles, is a digital marketing and data management technology company providing marketers, content owners and consumers tools to unlock the value of data. The Company’s technology unlocks data to reveal brands and content owners’ core consumers and their characteristics across marketing channels. SRAX is committed to building increasingly reliable data sets across many industry verticals, accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces, keeping those brands ahead in the competitive curve with high-quality data.

For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, May 17th, 2021 Uncategorized Comments Off on $SRAX Sequire Marks 5M Retail Investors, Hosts LD Micro Invitational

$SRAX Announces Partnership with Zoom Video Communications Inc. (NASDAQ: ZM) to Launch Sequire Audience

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, will partner with Zoom Video Communications (NASDAQ: ZM) to integrate Zoom and the Sequire Audience feature in the platform. Sequire is an exclusive investor intelligence and communications platform that companies use to track their investors’ behaviors and trends; the companies then utilize what they learn to attract and interact with current and potential shareholders, or other target audiences, across multiple channels. This new partnership will provide Sequire clients with the ability to host their own webinars, roadshows, annual meetings, earnings calls or standalone meetings within the Sequire platform. The new partnership means that customers will also be able schedule individual video meetings for smaller parties during conferences or earnings calls, much like having a private conversation or meeting with someone at an in-person event. “We have been using Zoom technology since the inception of our Sequire Audience product,” said SRAX founder and CEO Christopher Miglino in the press release. “This partnership gives us enhanced access to the Zoom tools and allows us to better integrate their technologies into our platform. The ability for issuers to create their own virtual roadshows and earnings calls is just one of the many new features inside our platform. Issuers can also keep track of event participants inside the Sequire platform, which will allow our clients to create better relationships with their existing and potential investors. . . . We have thrown a number of events of our own this year, but this partnership further enhances our ability to quickly launch conferences for other parties. We are excited to offer our platform to conference organizers.”

To view the full press release, visit https://ibn.fm/sKAjG

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, May 17th, 2021 Uncategorized Comments Off on $SRAX Announces Partnership with Zoom Video Communications Inc. (NASDAQ: ZM) to Launch Sequire Audience
Top Small Cap Market News